Start here if you're new
what it is
It develops cancer drugs for tumors, mostly in early testing.
how it gets paid
Product revenue is effectively $0—do not assign 20% of sales to a pipeline asset. Revenue is n/a / zero until there is real commercial sales.
what just happened
Q4 2024 EPS was -$6.20, and the company stayed deep in the red.
At a glance
C+ balance sheet — struggling to keep the lights on
-$24.00 fy2024 eps est
1.5 beta
~$41M market cap
micro cap
xvary composite: 35/100 — weak
What they do
It develops cancer drugs for tumors, mostly in early testing.
You are buying a tumor-only pipeline, not a broad drug empire. That matters because 15 employees are carrying the whole story. One Phase 1/2 program can move the stock more than a normal company’s whole quarter.
How they make money
n/a
annual revenue
Solnerstotug
$0M
SNS-102
$0M
SNS-103
$0M
SNS-201
$0M
University of Washington collaboration
$0M
The products that matter
lead immuno-oncology asset
Solnerstotug
pipeline asset · $0 revenue
this is still a pre-revenue clinical asset inside a company with $0 product revenue and -$23.52M EBITDA. until trial data improves the story, it is cost center first and product second.
pipeline
acquired oncology pipeline
Faeth Therapeutics Pipeline
$200M deal · 255% stock move
Deal headlines used ~$200M consideration—often stock/equity, not cash from a ~$41M mcap—read the exchange ratio in the filing before treating it like a cash check.
acquisition
capital raised to fund trials
Post-deal cash position
supports a pre-revenue model
management paired the acquisition with financing because this business still runs at a loss. with -$3.6M quarterly free cash flow in the current data, the real product right now is time.
runway
Key numbers
-$24.00
FY EPS est (loss)
Large per-share loss on a tiny float—treat as a forecast/feed line, not operating cash flow by itself.
$41M
market cap
The whole company is priced smaller than many single drug trial budgets, which makes every headline matter more.
15
employees
A 15-person team means you are backing a very small operation, not a fully built drug engine.
1.5
beta
A beta of 1.5 means the stock is built to swing harder than the market.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for SNSE right now.
source: institutional data · return history unavailable
What just happened
loss quarter · check vs est.
Q4 2024 EPS was -$6.20, and the company stayed deep in the red.
The quarterly loss improved from -$8.00 in late 2022 to -$6.20 in late 2024. Miss / beat tags need a consensus EPS line from your feed—this block does not print one. Still a loss, not a business model.
$0M
revenue
-$6.20
eps
n/a
n/a
the number that mattered
The key number was -$6.20 quarterly EPS—still spending far more than $0 product revenue.
source: quarterly EPS history, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is clinical and execution failure on the $200M Faeth Therapeutics acquisition.
med
The acquired pipeline does not validate
SNSE paid $200M for Faeth while the company itself is valued near $41M. If those assets stall, the market has to revalue the stock around a business with $0 product revenue.
This puts the post-deal rerating at risk. The 255% run can reverse if the new science does not earn credibility.
med
Clinical-stage biotech math is still brutal
Lead assets, including Solnerstotug and the acquired pipeline, are pre-revenue. No approved products means every trial readout carries outsized importance because there is no operating business to absorb disappointment.
One failed or delayed program would not just hurt sentiment. It would hit the core reason investors own the stock.
med
Cash burn can bring dilution back fast
Current data shows -$23.52M EBITDA and -$3.6M quarterly free cash flow. That is manageable only if trial progress justifies the spend and financing stays available.
If burn rises while milestones slip, new capital would likely be expensive for existing shareholders.
A pre-revenue company with $0 product revenue and -$23.52M EBITDA just tied its future to a $200M acquisition. If those assets fail to advance, there is no mature business underneath to cushion the fall.
source: institutional data · regulatory filings · risk analysis
Pay attention to
clinical
Faeth pipeline data in H2 2026
This is the biggest scheduled test of the $200M acquisition. Positive data keeps the rerating alive. Thin or delayed data makes the deal look expensive very quickly.
cash burn
Next quarterly free cash flow update
The current figure is -$3.6M. You want to see that number stay controlled while the company funds more development work.
valuation
Price versus analyst target band
The average one-year target is $33.15, with a low of $30.30 and a high of $36.75. At $29.50, the stock is already near the bottom of that published range, so upside needs fresh evidence.
governance
What the larger board does next
The board went from three members to five in feb 2026. Watch capital allocation, partnership moves, and whether management narrows the pipeline or keeps funding everything at once.
Analyst rankings
ai score
1/10
in human-speak, the model thinks SNSE has low odds of beating the market from here.
one-year target
$33.15
With the stock at $29.50, the target band implies some upside, but not much room for execution mistakes.
target range
$30.30–$36.75
That range tells you analysts are not modeling wildly different outcomes yet. The next clinical update can change that in a hurry.
source: institutional data
Institutional activity
institutional ownership data for SNSE is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$30
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive